| Expression System | HEK293 |
|---|
| Protein Tag | C-FLAG |
|---|
| Purity | > 95% by SDS-PAGE under reducing conditions |
|---|
| Endotoxin | < 1 EU per ug by the LAL method |
|---|
| Activity | Positive |
|---|
| Conjugate | Unconjugated |
|---|
| Species | Human |
|---|
| Accession Number | Q9H2C0 |
|---|
| Protein Sequence | Met1-Pro597 |
|---|
| Molecular Weight | The 605 amino acid recombinant Human Gigaxonin has the predicted molecular weight of 68.3 kD. The DTT-reduced protein migrates at approximately 65 kD on SDS-PAGE |
|---|
| Formulation | PBS with 300mM NaCl and 5mM DTT, pH 7.4 (0.2 μm filtered) |
|---|
| Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg and 500 µg size is bottled at lot specific concentration. |
|---|
| Purification | Affinity-M3 |
|---|
| Applications | ELISA |
|---|
| Format | Liquid |
|---|
| Reconstitution | NA |
|---|
| Shipping Condition | Cold Pack |
|---|
| Storage/Shelf Life | An unopened vial can be stored at 4°C for 2 weeks or at -20°C and below for six months. This stock solution should be aliquoted and stored at -70°C to minimize the freeze/thaw cycles. |
|---|
| Background Information | Gigaxonin is a protein involved in intermediate filament (IF) degradation and transport, primarily in nerve cells. Mutations in the GAN gene, which encodes gigaxonin, lead to Giant Axonal Neuropathy (GAN), a neurodegenerative disorder characterized by IF accumulation and aggregation in axons. Gigaxonin acts as a ubiquitin ligase adaptor, facilitating the breakdown of IFs through the ubiquitin-proteasome system. |
|---|
